# Pulmonary Hypertension: Assessment of Cell Therapy

> **NCT00469027** · PHASE1 · COMPLETED · sponsor: **Northern Therapeutics** · enrollment: 7 (actual)

## Conditions studied

- Hypertension, Pulmonary

## Interventions

- **BIOLOGICAL:** eNOS transfected EPCs will be delivered via a PA line

## Key facts

- **NCT ID:** NCT00469027
- **Lead sponsor:** Northern Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2016-10-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00469027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00469027, "Pulmonary Hypertension: Assessment of Cell Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00469027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*